10-Q: Nu-Med Plus Reports Q1 2024 Results, Announces Merger with YourSpace America

Nu-Med Plus reported a net loss for Q1 2024 and announced a merger with YourSpace America, Inc., which will result in a change of control and a shift in business focus.

Summary

• Nu-Med Plus, Inc. reported its financial results for the first quarter of 2024, showing no revenue and a net loss of $21,826, which is an improvement compared to a net loss of $28,204 in the same period of 2023.
• Operating expenses decreased to $20,579 from $26,971 year-over-year, primarily due to lower professional and consulting fees and rent expenses.
• The company's assets totaled $9,016, with current liabilities of $177,593, resulting in a working capital deficiency of $168,577.
• Nu-Med Plus is currently funded through June 30, 2024, and requires approximately $1,200,000 in additional funding over the next 12 months to cover development, operations, and administrative costs.
• The company has entered into a Share Exchange Agreement to merge with YourSpace America, Inc., which will result in YourSpace becoming a wholly-owned subsidiary of Nu-Med Plus.
• The merger will involve the issuance of 4,500,000 shares of Series A Preferred Stock and 1,000,000 shares of Series X Preferred Stock to YourSpace shareholders.
• The Series X Preferred Stock will give William R. Russ Colvin, the President, CEO, and Chief Investment Officer of YourSpace, majority voting control of the merged company.
• Following the merger, William Hayde will become Executive Chairman, and William R. Russ Colvin will become President and CEO of Nu-Med Plus.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, a lack of revenue, and a dependence on external funding, which are all negative indicators. The merger introduces uncertainty, and the company's going concern status raises serious concerns. The change of control and business focus also add to the negative sentiment.

Positives

• The net loss for Q1 2024 was lower than the net loss for Q1 2023, indicating some improvement in financial performance.
• Operating expenses decreased year-over-year, suggesting better cost management.
• The merger with YourSpace America, Inc. could provide new opportunities and potentially address the company's funding needs.

Negatives

• Nu-Med Plus reported no revenue for the first quarter of 2024.
• The company has a significant working capital deficiency of $168,577.
• The company requires substantial additional funding of $1,200,000 over the next 12 months to continue operations and development.
• The company's ability to continue as a going concern is in doubt due to its financial situation.
• The company's products are still in the development stage and have not yet received FDA approval.
• The merger will result in a change of control, which may introduce new risks and uncertainties.

Risks

• The company's ability to continue as a going concern is at risk due to its current financial situation.
• The company's products are still in the development stage and have not yet received FDA approval, which is a lengthy and expensive process.
• The company is dependent on external funding, and there is no guarantee that it will be able to secure the necessary capital.
• The merger with YourSpace America, Inc. introduces new risks and uncertainties, including integration challenges and potential changes in business strategy.
• The company's disclosure controls and procedures were deemed not effective to provide reasonable assurance that information is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms.

Future Outlook

The company anticipates needing $1,200,000 in additional financing over the next 12 months to cover development, operations, and administrative costs. The merger with YourSpace America, Inc. is expected to close, but the timing and impact are uncertain.

Management Comments

• Management believes that with the further refinement of our formulation, we can make and filter medical grade nitric oxide gas with minimal amounts of nitrogen dioxide.
• Management anticipates that selling our units earlier into the market as laboratory equipment or to international groups will pave the way for sales of our medical delivery devices.
• Management acknowledges that the funds on hand as of March 31, 2024, will not be sufficient to enable it to execute its business plan.

Industry Context

The company operates in the medical device field, specifically focusing on nitric oxide delivery systems. The market for nitric oxide therapies is growing, but it is also highly regulated and competitive. The merger with YourSpace America, Inc. represents a significant shift in the company's strategy and may indicate a move away from its original focus on nitric oxide technologies.

Comparison to Industry Standards

• Nu-Med Plus is an early-stage company with no revenue, which is not uncommon for companies in the medical device development phase.
• The company's reliance on external funding and its going concern issues are typical challenges for pre-revenue companies in this sector.
• The merger with YourSpace America, Inc. is a significant strategic move, and its success will depend on the integration of the two companies and the execution of the new business plan.
• Compared to established medical device companies like Medtronic or Johnson & Johnson, Nu-Med Plus is significantly smaller and has a much higher risk profile.
• The company's focus on nitric oxide delivery systems puts it in competition with companies like Mallinckrodt, which produces Inomax, a currently approved nitric oxide therapy.

Management Changes

Related Party Transactions

• The company has accounts payable to a related party totaling $46,589 as of March 31, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be affected by the merger and potential changes in the company's operations.
• Customers and suppliers may experience uncertainty due to the company's financial situation and strategic shift.
• Creditors face increased risk due to the company's working capital deficiency and need for additional funding.

Next Steps

• The company needs to secure additional funding to continue operations and product development.
• The company needs to complete the merger with YourSpace America, Inc.
• The company needs to integrate the operations of the two companies.
• The company needs to develop a new business plan and strategy following the merger.
• The company needs to address the deficiencies in its disclosure controls and procedures.

Key Dates

Keywords

Nu-Med Plus, YourSpace America, Merger, Nitric Oxide, Medical Device, FDA Approval, Financial Results, Share Exchange Agreement, Preferred Stock, Going Concern